137 related articles for article (PubMed ID: 38237604)
1. Preclinical toxicity evaluation of novel antibacterial contezolid acefosamil in rats and dogs.
Wang W; Li Z; Gordeev MF; Yuan H
J Appl Toxicol; 2024 May; 44(5):770-783. PubMed ID: 38237604
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic rationale for intravenous contezolid acefosamil followed by oral contezolid dosage regimens.
Bulitta JB; Fang E; Stryjewski ME; Wang W; Atiee GJ; Stark JG; Hafkin B
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0140023. PubMed ID: 38415667
[TBL] [Abstract][Full Text] [Related]
3. Nonclinical Evaluation of Antibacterial Oxazolidinones Contezolid and Contezolid Acefosamil with Low Serotonergic Neurotoxicity.
Wang W; Voss KM; Liu J; Gordeev MF
Chem Res Toxicol; 2021 May; 34(5):1348-1354. PubMed ID: 33913699
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Antibacterial Contezolid Acefosamil: Innovative
Liu J; Wang W; Wang C; Zhang L; Zhang X; Liu S; Xu Y; Wang H; Dai Q; Liu C; Wang X; Yuan Z; Gordeev MF
ACS Med Chem Lett; 2022 Jul; 13(7):1030-1035. PubMed ID: 35859881
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of the safety, tolerability, and pharmacokinetics of contezolid acefosamil after intravenous and oral administration in healthy Chinese subjects.
Yang H; Jin Y; Wang H; Yuan H; Wang J; Li S; Hu Y; Yang H; Li X; Liang H; Wu J; Cao G; Zhang J
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0079623. PubMed ID: 37902402
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Disposition of Contezolid in Humans: Resolution of a Disproportionate Human Metabolite for Clinical Development.
Wu X; Meng J; Yuan H; Zhong D; Yu J; Cao G; Liu X; Guo B; Chen Y; Li Y; Shi Y; Gordeev MF; Wu J; Zhang J
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0040921. PubMed ID: 34398672
[TBL] [Abstract][Full Text] [Related]
7. In vivo pharmacodynamic study of contezolid acefosamil, a prodrug of contezolid for oral and intravenous administration.
Wang XK; Yu J; Xie CY; Hu XX; Nie TY; Li X; Wang PH; Li GQ; Yuan H; Yang XY; Li CR; You XF
J Antimicrob Chemother; 2023 Jul; 78(7):1632-1636. PubMed ID: 37202829
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients.
Li L; Wu H; Chen Y; Yuan H; Wu J; Wu X; Zhang Y; Cao G; Guo B; Wu J; Zhao M; Zhang J
Clin Ther; 2020 May; 42(5):818-829. PubMed ID: 32389326
[TBL] [Abstract][Full Text] [Related]
9. Advances in contezolid: novel oxazolidinone antibacterial in Gram-positive treatment.
Zhang GX; Liu TT; Ren AX; Liang WX; Yin H; Cai Y
Infection; 2024 Jun; 52(3):787-800. PubMed ID: 38717734
[TBL] [Abstract][Full Text] [Related]
10. Contezolid in complicated skin and soft tissue infection.
Kaul G; Dasgupta A; Chopra S
Drugs Today (Barc); 2022 Jul; 58(7):315-326. PubMed ID: 35851867
[TBL] [Abstract][Full Text] [Related]
11. A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity
Guo Q; Xu L; Tan F; Zhang Y; Fan J; Wang X; Zhang Z; Li B; Chu H
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0088921. PubMed ID: 34460305
[TBL] [Abstract][Full Text] [Related]
12. Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis.
Wu J; Wu H; Wang Y; Chen Y; Guo B; Cao G; Wu X; Yu J; Wu J; Zhu D; Guo Y; Yuan H; Hu F; Zhang J
Clin Ther; 2019 Jun; 41(6):1164-1174.e4. PubMed ID: 31126694
[TBL] [Abstract][Full Text] [Related]
13. A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections.
Zhao X; Huang H; Yuan H; Yuan Z; Zhang Y
J Antimicrob Chemother; 2022 May; 77(6):1762-1769. PubMed ID: 35265985
[TBL] [Abstract][Full Text] [Related]
14.
Carvalhaes CG; Duncan LR; Wang W; Sader HS
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32778552
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Effect of Contezolid (MRX-I) on the Corrected QT Interval in a Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study in Healthy Chinese Volunteers.
Wu J; Cao G; Wu H; Chen Y; Guo B; Wu X; Yu J; Ni K; Qian J; Wang L; Wu J; Wang Y; Yuan H; Zhang J; Xi Y
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32229495
[TBL] [Abstract][Full Text] [Related]
16. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
[TBL] [Abstract][Full Text] [Related]
17. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin.
Kratz F; Ehling G; Kauffmann HM; Unger C
Hum Exp Toxicol; 2007 Jan; 26(1):19-35. PubMed ID: 17334177
[TBL] [Abstract][Full Text] [Related]
18. New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile.
Gordeev MF; Yuan ZY
J Med Chem; 2014 Jun; 57(11):4487-97. PubMed ID: 24694071
[TBL] [Abstract][Full Text] [Related]
19. Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment.
Li B; Liu Y; Luo J; Cai Y; Chen M; Wang T
Front Pharmacol; 2023; 14():1157437. PubMed ID: 37168994
[TBL] [Abstract][Full Text] [Related]
20. Drug Degradation Caused by
Pi R; Chen X; Meng J; Liu Q; Chen Y; Bei C; Wang C; Gao Q
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0103422. PubMed ID: 36190243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
